MedPath

广东东阳光药业股份有限公司

Ownership
-
Established
2003-12-29
Employees
-
Market Cap
-
Website
https://www.dyg.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

39

NMPA:39

Drug Approvals

Galantamine Hydrobromide Orally Disintegrating Tablets

Product Name
氢溴酸加兰他敏口腔崩解片
Approval Number
国药准字H20244023
Approval Date
Jun 18, 2024
NMPA

Galantamine Hydrobromide Orally Disintegrating Tablets

Product Name
氢溴酸加兰他敏口腔崩解片
Approval Number
国药准字H20244021
Approval Date
Jun 18, 2024
NMPA

Galantamine Hydrobromide Orally Disintegrating Tablets

Product Name
氢溴酸加兰他敏口腔崩解片
Approval Number
国药准字H20244022
Approval Date
Jun 18, 2024
NMPA

Ritonavir Tablets

Product Name
利托那韦片
Approval Number
国药准字H20234359
Approval Date
Oct 24, 2023
NMPA

Ketoprofen Gel

Product Name
酮洛芬凝胶
Approval Number
国药准字H20183381
Approval Date
Jul 10, 2023
NMPA

Adapalene Gel

Product Name
阿达帕林凝胶
Approval Number
国药准字H20183078
Approval Date
Mar 7, 2023
NMPA

Oseltamivir Phosphate for Suspension

Product Name
磷酸奥司他韦干混悬剂
Approval Number
国药准字H20223198
Approval Date
Apr 8, 2022
NMPA

Oseltamivir Phosphate Capsules

Product Name
磷酸奥司他韦胶囊
Approval Number
国药准字H20223173
Approval Date
Mar 29, 2022
NMPA

Oseltamivir Phosphate Capsules

Product Name
磷酸奥司他韦胶囊
Approval Number
国药准字H20223174
Approval Date
Mar 29, 2022
NMPA

Oseltamivir Phosphate Capsules

Product Name
磷酸奥司他韦胶囊
Approval Number
国药准字H20223172
Approval Date
Mar 29, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.